A non-randomised phase 2 pilot study of accelerated BEP [bleomycin etoposide platinum] chemotherapy for intermediate and high risk metastatic germ cell tumours.

Trial Profile

A non-randomised phase 2 pilot study of accelerated BEP [bleomycin etoposide platinum] chemotherapy for intermediate and high risk metastatic germ cell tumours.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Bleomycin (Primary) ; Cisplatin (Primary) ; Etoposide (Primary) ; Pegfilgrastim (Primary)
  • Indications Germ cell and embryonal neoplasms; Peritoneal cancer; Testicular cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Accelerated-BEP
  • Most Recent Events

    • 06 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
    • 03 Feb 2010 Planned end date changed from 31 Dec 2009 to 18 Jan 2010 as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top